๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shijiazhuang
Clinical trial register · China

Clinical Trials in Shijiazhuang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Hebei Medical University Fourth Hospital43 Novartis Pharmaceuticals12 BeOne Medicines9 Beijing InnoCare Pharma Tech Co., Ltd.8 Bristol-Myers Squibb8
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shijiazhuang

341 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease
NCT04944043Chronic Graft Versus Host Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
45
Hefei, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Tianjin
2021-06-25
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Active, closed
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Active, closed
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
NCT04848753Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
663
Bengbu, Hefei, Jiangmen, Shenzhen, Shijiazhuang, Anyang, Xinxiang, Zhengzhou
2021-05-12
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
Novo Nordisk A/S
Phase 3
1,205
Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Changzhou
2021-04-01
Active, closed
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
NCT04954001Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1/2
160
Beijing, Guangzhou, Hangzhou, Shanghai, Shijiazhuang, Wuhan
2021-03-26
Recruiting
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
NCT06189391Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
MSD R&D (China) Co., Ltd.
Phase 1
100
Beijing, Xiameng, Guangzhou, Shijiazhuang, Zhengzhou, Nanchang, Changchun, Jinan
2021-03-16
Active, closed
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT04765657Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242Pediatric Migraine
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Recruiting
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
NCT07309991Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy, PaO2
Sun Yat-sen University
Observational
2,500
Guangzhou, Shantou, Shijiazhuang, Shanghai, Chengdu, Nanchong
2021-01-01
Recruiting
Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
NCT06375798Breast Cancer, HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
Observational
620
Shijiazhuang
2020-11-19
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Recruiting
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
NCT04494503Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
Phase 1/2
123
Beijing, Chongqing, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhenzhou, Wuhan
2020-08-31
Recruiting
Study on Multimodal Imaging and Molecular Imaging Techniques in Degenerative Dementia
NCT06534658Alzheimer Disease, Image
Ruijin Hospital
Observational
1,000
Beijing, Hanzhong, Cangzhou, Shijiazhuang, Qingdao, Shanghai, Shenyang
2020-07-30
Active, closed
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Active, closed
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
NCT04290793Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3
113
Shijiazhuang
2020-03-01
Recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344Neoplasms, Tenosynovial Giant Cell Tumor
Abbisko Therapeutics Co, Ltd
Phase 1
276
Beijing, Guangdong, Shijiazhuang, Zhengzhou, Nanjing, Shenyang, Shanghai, Xian
2020-01-20
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Observational
500
Chengdu, Beijing, Changchun, Guangzhou, Jinan, Nanchang, Qingdao, Shijiazhuang
2019-12-02
Recruiting
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
NCT04138719Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel
Hebei Medical University Fourth Hospital
Phase 2
520
Shijiazhuang
2019-11-20
Recruiting
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
NCT04159142Triple Negative Breast Cancer, Nab-paclitaxel
Hebei Medical University Fourth Hospital
Phase 2
414
Shijiazhuang
2019-11-20
Recruiting
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
NCT06550713Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
100
Beijing, Shijiazhuang, Harbin, Shanghai, Chengdu, Tianjin
2019-10-22
Active, closed
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307Asthma
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Recruiting
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
NCT03964753Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2
202
Shijiazhuang
2019-04-24
Active, closed
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Recruiting
Researches About Proximal Humerus Fractures
NCT04523415Proximal Humeral Fracture
Hebei Medical University Third Hospital
Observational
800
Shijiazhuang
2019-01-01
Recruiting
The Research About Acute Compartment Syndrome
NCT04529330Acute Compartment Syndrome
Hebei Medical University Third Hospital
Observational
80
Shijiazhuang
2019-01-01
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Heifei, Shanghai, Beijing, Fuzhou Fujian, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2018-12-27
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou, Changchun
2018-12-07
Recruiting
Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery
NCT03349762Colorectal Cancer
Xi Shan Wang
Observational
3,060
Shijiazhuang, Harbin, Wuhan, Changsha, Changzhou, Xuzhou, Yangzhou, Anshan
2018-11-02
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
AbbVie
Phase 3
1,336
Guangzhou, Shijiazhuang, Wuhan, Changsha, Nanchang, Shanghai, Chengdu, Tianjin
2018-04-09
Active, closed
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT02966756Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
AbbVie
Phase 2
66
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2017-10-12
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naรฏve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
AbbVie
Phase 3
443
Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Changchun, Shanghai
2017-02-02
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566Breast Cancer
Eli Lilly and Company
Phase 3
463
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2016-12-05
Active, closed
Sympathetic Mapping/ Ablation of Renal Nerves Trial
NCT02761811Hypertension
SyMap Medical (Suzhou), Ltd.
Not applicable
220
Beijing, Chongqing, Shenzhen, Shijiazhuang, Daqing, Wuhan, Nanjing, Xuzhou
2016-06-30
Active, closed
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
NCT02767804Non-small Cell Lung Cancer
Xcovery Holdings, Inc.
Phase 3
290
Hefei, Beijing, Fuzhou, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanjing
2016-06
Recruiting
China Registry for Genetic / Metabolic Liver Diseases
NCT03131427Genetic/Metabolic Liver Diseases
Beijing Friendship Hospital
Observational
20,000
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Shanghai, Chengdu, Tianjin, รœrรผmqi
2015-06-13
Active, closed
The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC๏ผ‰
NCT06828718Esophageal Carcinoma
Hebei Medical University Fourth Hospital
Observational
1,000
Shijiazhuang
2015-01-01
Recruiting
Nutrition Support on Outcomes and Cost-effectiveness for Patients at Risk
NCT00289380Malnutrition, Nutritional Risk
Peking Union Medical College
Observational
2,000
Beijing, Chongqing, Guangzhou, Nanning, Shijiazhuang, Tianjin, Wuhan, Nanjing
2005-01
Rows per page Showing 301–341 of 341
Previous 2 3 4
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shijiazhuang?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 341 of those studies with a site in Shijiazhuang.

How many clinical trials are recruiting in Shijiazhuang?

209 of the 341 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 52 have not yet opened recruitment, 75 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.